Trial Profile
Treatment with PROSTVAC, nilutamide, and combination therapy in non-metastatic androgen independent prostate cancer patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2010
Price :
$35
*
At a glance
- Drugs Rilimogene galvacirepvec (Primary) ; Rilimogene galvacirepvec-rilimogene glafolivec (Primary) ; Rilimogene glafolivec (Primary) ; Nilutamide
- Indications Prostate cancer
- Focus Therapeutic Use
- 05 Nov 2010 New trial record.
- 21 May 2002 Interim results presented at the 38th Annual Meeting of the American Society of Clinical Oncology.